XML 73 R54.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Revenues (Details) $ in Millions | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2018 USD ($) | Sep. 30, 2018 USD ($) | Jun. 30, 2018 USD ($) | Mar. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Sep. 30, 2017 USD ($) | Jun. 30, 2017 USD ($) | Mar. 31, 2017 USD ($) | Dec. 31, 2018 USD ($) segment | Dec. 31, 2017 USD ($) | Dec. 31, 2016 USD ($)
Revenue from Contract with Customer [Abstract] |  |  |  |  |  |  |  |  |  |  |
Number of operating segments | segment |  |  |  |  |  |  |  |  | 1 |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  |  |  |  |  |  |  | $ 23,747 | $ 22,849 | $ 22,991
US [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  |  |  |  |  |  |  | 18,358 | 18,029 | 18,326
ROW [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  |  |  |  |  |  |  | 5,389 | 4,820 | 4,665
Product sales [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales | $ 6,001 | $ 5,510 | $ 5,679 | $ 5,343 | $ 5,569 | $ 5,453 | $ 5,574 | $ 5,199 | 22,533 | 21,795 | 21,892
Hedging gains |  |  |  |  |  |  |  |  |  |  | 308
Product sales [Member] | US [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 17,429 | 17,131 | 17,325
Product sales [Member] | ROW [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 5,104 | 4,664 | 4,567
Enbrel® (etanercept) [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 5,014 | 5,433 | 5,965
Enbrel® (etanercept) [Member] | US [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 4,807 | 5,206 | 5,719
Enbrel® (etanercept) [Member] | ROW [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 207 | 227 | 246
Neulasta® (pegfilgrastim) [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 4,475 | 4,534 | 4,648
Neulasta® (pegfilgrastim) [Member] | US [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 3,866 | 3,931 | 3,925
Neulasta® (pegfilgrastim) [Member] | ROW [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 609 | 603 | 723
Prolia® (denosumab) [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 2,291 | 1,968 | 1,635
Prolia® (denosumab) [Member] | US [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 1,500 | 1,272 | 1,049
Prolia® (denosumab) [Member] | ROW [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 791 | 696 | 586
Aranesp® (darbepoetin alfa) [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 1,877 | 2,053 | 2,093
Aranesp® (darbepoetin alfa) [Member] | US [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 942 | 1,114 | 1,082
Aranesp® (darbepoetin alfa) [Member] | ROW [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 935 | 939 | 1,011
XGEVA® (denosumab) [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 1,786 | 1,575 | 1,529
XGEVA® (denosumab) [Member] | US [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 1,338 | 1,157 | 1,115
XGEVA® (denosumab) [Member] | ROW [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 448 | 418 | 414
Sensipar® / Mimpara® (cinacalcet) [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 1,774 | 1,718 | 1,582
Sensipar® / Mimpara® (cinacalcet) [Member] | US [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 1,436 | 1,374 | 1,240
Sensipar® / Mimpara® (cinacalcet) [Member] | ROW [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 338 | 344 | 342
EPOGEN® (epoetin alfa) [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 1,010 | 1,096 | 1,282
EPOGEN® (epoetin alfa) [Member] | US [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 1,010 | 1,096 | 1,282
EPOGEN® (epoetin alfa) [Member] | ROW [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 0 | 0 | 0
Other products [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 4,306 | 3,418 | 3,158
Other products [Member] | US [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 2,530 | 1,981 | 1,913
Other products [Member] | ROW [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total product sales |  |  |  |  |  |  |  |  | 1,776 | 1,437 | 1,245
Other revenues [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  |  |  |  |  |  |  | 1,214 | 1,054 | 1,099
Other revenues [Member] | US [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  |  |  |  |  |  |  | 929 | 898 | 1,001
Other revenues [Member] | ROW [Member] |  |  |  |  |  |  |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  |  |  |  |  |  |  | $ 285 | $ 156 | $ 98

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Gain (loss) incurred in hedging activities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959 + Details
Name: | us-gaap_GainLossOnOilAndGasHedgingActivity
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + References No definition available. + Details
Name: | us-gaap_NumberOfOperatingSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_EnbrelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_NeulastaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_ProliaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_AranespMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_XgevaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_SensiparMimparaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_EpogenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_OtherProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |